Volume 14, Number 8—August 2008
Dispatch
Oseltamivir Prescribing in Pharmacy-Benefits Database, United States, 2004–20051
Justin R. Ortiz*2
, Laurie Kamimoto*, Ronald E. Aubert†, Jianying Yao†, David K. Shay*, Joseph S. Bresee*, and Robert S. Epstein†
, Laurie Kamimoto*, Ronald E. Aubert†, Jianying Yao†, David K. Shay*, Joseph S. Bresee*, and Robert S. Epstein†Table 1
Anti-influenza drug prescription rates/100,000 enrollees and proportions of all anti-influenza drug prescriptions, United States, weeks 36–44, 2004 and 2005*
| Medication | Anti-influenza prescription rates/100,000 enrollees of all ages, weeks 36–44 |
% Total anti-influenza prescriptions |
|||||
|---|---|---|---|---|---|---|---|
| 2004 | 2005 | Rate ratio (2005/2004) | 95% Confidence interval | 2004 | 2005 | ||
| Neuraminidase inhibitors | |||||||
| Oseltamivir |
27.3 |
133 |
4.88 |
4.79–4.97 |
36.99 |
76.89 |
|
| Zanamivir | 0.35 | 1.39 | 4.00 | 3.38–4.75 | 0.47 | 0.80 | |
| Adamantanes | |||||||
| Amantadine |
41.7 |
36.3 |
0.87 |
0.85–0.89 |
56.53 |
20.93 |
|
| Rimantadine | 4.43 | 2.37 | 0.54 | 0.50–0.58 | 6.00 | 1.37 | |
| All anti-influenza drugs | 80.0 | 173.2 | 2.17 | 2.14–2.19 | 100 | 100 | |
*Sums do not equal 100% because of rounding.
1This study was presented, in part, at the Infectious Diseases Society of America annual meeting in Toronto, Ontario, Canada, October 14, 2006, and in poster form at the Options for the Control of Influenza Conference, Toronto, June 17, 2007.
2Current affiliation: University of Washington, Seattle, WA, USA.
